CN108272740B - 组合物及含有该组合物的痤疮修复化妆品 - Google Patents
组合物及含有该组合物的痤疮修复化妆品 Download PDFInfo
- Publication number
- CN108272740B CN108272740B CN201810264475.XA CN201810264475A CN108272740B CN 108272740 B CN108272740 B CN 108272740B CN 201810264475 A CN201810264475 A CN 201810264475A CN 108272740 B CN108272740 B CN 108272740B
- Authority
- CN
- China
- Prior art keywords
- cosmetics
- acne
- composition
- cell
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 62
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 61
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000008439 repair process Effects 0.000 title abstract description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000004471 Glycine Substances 0.000 claims abstract description 19
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims abstract description 18
- 229960001860 salicylate Drugs 0.000 claims abstract description 18
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims abstract description 17
- KIENGQUGHPTFGC-JLAZNSOCSA-N L-ascorbic acid 6-phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O KIENGQUGHPTFGC-JLAZNSOCSA-N 0.000 claims abstract description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 15
- 239000011777 magnesium Substances 0.000 claims abstract description 15
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 13
- 244000146462 Centella asiatica Species 0.000 claims abstract description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 93
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 60
- 238000003756 stirring Methods 0.000 claims description 44
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 20
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 20
- 229920002674 hyaluronan Polymers 0.000 claims description 20
- 229960003160 hyaluronic acid Drugs 0.000 claims description 20
- 238000006384 oligomerization reaction Methods 0.000 claims description 20
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 19
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 19
- 229920002498 Beta-glucan Polymers 0.000 claims description 19
- 229960000458 allantoin Drugs 0.000 claims description 19
- 229960003237 betaine Drugs 0.000 claims description 19
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004475 Arginine Substances 0.000 claims description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 238000007792 addition Methods 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 14
- 229910021641 deionized water Inorganic materials 0.000 claims description 14
- 229920001285 xanthan gum Polymers 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- -1 nicotinoyl Chemical group 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 9
- 230000008591 skin barrier function Effects 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 231100000241 scar Toxicity 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 230000001771 impaired effect Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000011382 collagen catabolic process Effects 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 11
- 229960003966 nicotinamide Drugs 0.000 abstract description 11
- 235000005152 nicotinamide Nutrition 0.000 abstract description 11
- 239000011570 nicotinamide Substances 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 10
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract description 8
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 4
- 239000000706 filtrate Substances 0.000 abstract description 4
- 229960004275 glycolic acid Drugs 0.000 abstract description 4
- 235000015206 pear juice Nutrition 0.000 abstract description 4
- 229940084038 salix alba bark extract Drugs 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 51
- 238000012360 testing method Methods 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 25
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000003255 anti-acne Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940055019 propionibacterium acne Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036564 melanin content Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 229960002256 spironolactone Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 235000013717 Houttuynia Nutrition 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WWRCMNKATXZARA-UHFFFAOYSA-N 1-Isopropyl-2-methylbenzene Chemical compound CC(C)C1=CC=CC=C1C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000557821 Azadirachta Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 208000003669 immune deficiency disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及化妆品领域,特别涉及组合物及含有该组合物的痤疮修复化妆品。该化合物包括如下组分:包括羟基乙酸、乳酸杆菌/梨汁发酵产物滤液、白柳树皮提取物、烟酰胺、辛酰基甘氨酸、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌、L‑抗坏血酸磷酸酯镁和积雪草提取物。该组合物及含有该组合物的痤疮修复化妆品具有修复青春痘、促进愈合的功效。
Description
技术领域
本发明涉及化妆品领域,特别涉及组合物及含有该组合物的痤疮修复化妆品。
背景技术
痤疮是一种与内分泌功能失调有关的毛囊、皮脂腺慢性炎症性皮肤病,是皮肤科常见的病和多发病,其临床表现为颜面部白头或黑头粉刺,丘疹,脓包,结节,囊肿,凹陷或增生性瘢痕等,严重影响患者的生活质量。痤疮的发病机制可能与皮脂腺分泌增多,毛囊口上皮角化过度,痤疮丙酸杆菌活跃或体内雄性激素水平增高有关。痤疮临床发病于青春期,她将影响到个人外貌及自尊,甚至引发心里疾病,导致生活亚健康状态。痤疮发病率高,研发发现其普遍发生在16-19岁男孩和14-17岁女孩中,在不同种族12-24岁青少年发病率高达85%,虽然痤疮影响大多数是青少年,但它在成人中仍普遍存在,比如20-30岁范围内占40-50%,甚至报道10-20%的40岁以上人亦患有痤疮。
由于痤疮患者以青春期男女较多,常可对容貌产生影响,而该人群更注重自己的外貌形象,故痤疮对患者的心理及生活质量产生较为严重的负面影响,造成患者正常生活,学习,工作,婚姻,社会交际,情绪,自信心等受到严重影响。国内外研究结果表明,痤疮会使患者产生情绪低落,焦虑,抑郁,精神紧张等不良的情绪,并因此产生严重的社会心理问题。最常见的是自尊心,自信心受损,产生尴尬,抑郁,紧张的心理,导致患者社交障碍和影响学习和工作,严重时甚至会导致患者产生自杀倾向。
随着临床医学模式从单纯的生物医学模式向生物-社会-心理医学模式转变,痤疮不仅仅是单纯生理赏的疾病,它已称为一种严重影响个人心理健康的疾病,能影响患者的容貌,情感,社交,人际关系,就业等方面,引起患者意志力减弱,产生自杀心理,焦虑抑郁,精神恍惚等症状。
目前针对痤疮的外用药物护理主要以下:
2.1维A酸
维A酸类药物外用治疗痤疮,可以消除皮脂腺堵塞,同事减少痤疮丙酸杆菌的菌群数量。但局部使用维A酸可引起不良反应,最常见的副作用对皮肤的刺激,包括干燥,红斑,刺痛,瘙痒等。
2.1过氧化苯甲酰
过氧化苯甲酰是一种特异性的微生物抑制剂,尤其对痤疮丙酸杆菌和金黄色葡萄球菌具有公安度选择性,可用于抑制毛囊内皮脂腺内的微生物并杀灭丙酸痤疮杆菌,从而改善炎症和非炎性皮损的星狂。但由于此成分对皮肤刺激性大,限制其应用。
2.3光动力治疗
光动力学是一种结合光,光敏剂和组织内分子氧,通过光动力学反应生成活性氧并选择性损伤靶向组织的治疗方法。
人体对痤疮丙酸杆菌产生卟啉光吸收的最高峰为蓝光(415nm),其组织穿透力较弱,因此蓝光主要对于轻中度具有炎性皮损的痤疮患者有较好的治疗效果。红光(633nm)具有更强组织穿透力,不仅能刺激巨噬细胞释放细胞因子,达到一定的抗炎作用,还可以活化细胞中的纤维母细胞产生生长因子,诱导表达新胶原,促进对损伤组织的修复,因此,红光对深层次的皮损治疗效果较好。
强脉冲光
IPL所用原理是选择性光热解,常用的波长530-750nm,其靶组织主要是黑色素和血红蛋白,他们在吸收光子后被加热,破坏,最终被免疫细胞清除。IPL在临床应用于瘢痕,炎症,色素沉着的治疗,并具有创伤小,恢复快的有点。
采用光动力学治疗痤疮,主要针对细菌消灭,炎症消除,存在不足,单次治疗成本高,治疗周期长,且需要每月到医院或专业机构进行为其4-6月治疗。
2.4抗生素
红霉素,氯霉素,克林霉素,可用酒精或丙二醇配制成适宜浓度的外用药,但注意抗生素的耐药性问题,应慎重使用抗生素。外用抗生素与外用维A酸一样,可以引起皮肤局部红肿,干燥脱皮和瘙痒症状。
2.5雌激素
女性痤疮患者可采用抗雄性技术治疗,其治疗药物包括避孕药,螺内酯,西咪替丁。避孕药由乙炔雌二醇和环丙孕酮组成,是抗雄激素最常见的药物。研究显示,避孕药联用降血糖药二甲双胍治疗多卵性综合症,结果表面治疗方案可改善雄激素过多症状,缩减卵巢体积,但长期使用避孕药会影响机体糖代谢,引发高胰岛素血症。
螺内酯可选择性第破坏性腺和肾上腺的细胞色素P450酶系统,抑制雄激素生成酶活性,减少雄激素的产生。但螺内酯会产生高钾血症,肾功能损害和胃肠道反应等不良反应。
西咪替丁具有较弱的抗雄激素作用,能竞争性阻断DHT与受体结合,但不影响血清雄激素水平。但资料痤疮并不明显,且伴随精神紊乱,咽喉疼痛发热等不良反应。
2.5护理产品
市面上大多数针对青春痘护理的产品,绝大多数停留在清洁控油,化学剥离角质的应用层面,针对痤疮丙酸杆菌诱发炎症,细胞释放细胞因子,诱导免疫应答角度抑制痤疮导致的组织损伤与破坏。市面劣质化妆品,在配方中添加激素成分,严重破坏消费者皮肤屏障,导致激素脸的问题肌肤。
因此,提供一种修复青春痘、促进愈合的组合物及化妆品具有重要的现实意义。
发明内容
有鉴于此,本发明提供一种组合物及含有该组合物的痤疮修复化妆品。该组合物及含有该组合物的痤疮修复化妆品具有修复青春痘、促进愈合的功效。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种组合物,包括如下组分:包括羟基乙酸、乳酸杆菌/梨汁发酵产物滤液、白柳树皮提取物、烟酰胺、辛酰基甘氨酸、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌、L-抗坏血酸磷酸酯镁和积雪草提取物。
在本发明的一些具体实施方案中,以质量份计,所述组合物包括:
在本发明的一些具体实施方案中,所述组合物还包括甘油、丙二醇、丁二醇、寡聚透明质酸、β-葡聚糖、甜菜碱、尿囊素、精氨酸、薄荷氧基丙二醇、PEG-60氢化蓖麻油、乙基己基甘油、甘油辛酸酯、o-伞花烃-5-醇、黄檗树皮提取物、中国地黄根提取物、印度楝树叶提取物、黄芩根提取物、鱼腥草提取物、野大豆提取物中的一种或两者以上的混合物。
在本发明的一些具体实施方案中,以质量份计,所述组合物包括:
其中,以质量分数计,所述痤疮克星的组成为:
本发明还提供了所述的组合物在制备治疗和/或预防皮肤屏障受损、青春痘发红发热炎、局部色素沉着、青春痘导致胶原蛋白降解与合成失衡形成的皮肤凹陷和疤痕的药物和/或化妆品中的应用。
本发明还提供了所述的组合物在制备治疗和/或预防痤疮中的应用。
本发明还提供了一种化妆品,包括所述的组合物以及化妆品中可接受的辅料。
在本发明的一些具体实施方案中,以质量百分数计,所述化妆品包括:
其中,所述痤疮克星的组成为:
在本发明的一些具体实施方案中,以质量百分数计,所述化妆品包括:
在本发明的一些具体实施方案中,以质量百分数计,所述化妆品包括:
在本发明的一些具体实施方案中,以质量百分数计,所述化妆品包括:
在本发明的一些具体实施方案中,所述化妆品为祛痘洁面乳、祛痘水、祛痘精华、祛痘膏或祛痘面膜。凡是化妆品中可接受的剂型均在本发明的保护范围之内,本发明在此不做限定。
本发明还提供了所述的化妆品的制备方法,包括如下步骤:
步骤1:称量去离子水;
步骤2:分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸、烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌、辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
步骤3:分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
步骤4:降低搅拌速率至150~200r/min,温度降至45~55℃,称取积雪草提取物和痤疮克星,搅拌20~30min;
步骤5:温度降低45~50℃,称量防腐剂PHL和薄荷氧基丙二醇,搅拌10min冷却。
本发明还提供了所述的化妆品或如所述的制备方法制得的化妆品在制备治疗和/或预防皮肤屏障受损、青春痘发红发热炎、局部色素沉着、青春痘导致胶原蛋白降解与合成失衡形成的皮肤凹陷和疤痕的药物和/或化妆品中的应用。
本发明还提供了所述的化妆品或如所述的制备方法制得的化妆品在制备治疗和/或预防痤疮中的应用。
本发明采用寡聚透明质酸、烟酰胺、吡咯烷酮羧酸锌进行皮肤屏障天然保湿因子外源性补充,降低水分散失,采用辛酰基甘氨酸修复皮肤酸性屏障,有效抑制微生物增殖生长。本发明采用的硅烷二醇水杨酸酯,保护角质细胞,稳固皮肤的第一道屏障;保护的酶环境,使催化细胞生存反应正常;保护蛋白质,皮肤结构保护、功能正常化。
本发明采用薄荷氧基丙二醇降低皮表温度,给痤疮患者舒适愉悦的清凉感。
本发明采用L-抗坏血酸磷酸酯镁还原黑色素中间体、采用烟酰胺抑制黑色素向角质形成细胞转移,采用羟基乙酸和硅烷二醇水杨酸酯、白柳树皮提取物和乳酸杆菌/梨汁发酵滤液协同作用温和剥离角质层,促进皮肤新陈代谢,有效抑制色素沉着。
本发明采用积雪草提取物和L-抗坏血酸磷酸酯镁协同抑制基质金属蛋白酶MMP-2、MMP-9的活性,调节TIMP的活性,有效避免青春痘导致皮损愈合形成的凹陷和疤痕。
本发明针对痤疮引起皮损后遗症问题,针对皮肤屏障受损、青春痘发红发热炎、局部色素沉着、青春痘导致胶原蛋白降解与合成失衡形成的皮肤凹陷和疤痕为靶点进行有效控制。
本发明广泛应用于肌肤护理相关的产品中,如祛痘洁面乳,祛痘水,祛痘精华,祛痘膏,祛痘面膜等产品中。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示皮肤水分散失检测结果;
图2示陈纤维细胞增殖检测结果;
图3示细胞黑色素含量检测结果;
图4示祛痘功效评价试验中一名参与评估人员皮肤3D图;其中,图A的日期为2017.05.08,图B的日期为2017.05.15,图C的日期为2017.05.22,图D的日期为2017.06.06。
具体实施方式
本发明公开了一种组合物及含有该组合物的痤疮修复化妆品,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明提供的组合物及含有该组合物的痤疮修复化妆品中所用原料、辅料及试剂均可由市场购得。
其中,痤疮克星购自一丸公司;
本发明中所述的痤疮克星成分组成:
组分 | 配比% |
水 | 46.7975 |
丁二醇 | 40.3755 |
羟基乙酸 | 5.6 |
PEG-60氢化蓖麻油 | 4 |
乙基己基甘油 | 1 |
甘油辛酸酯 | 1 |
乳酸杆菌/梨汁发酵产物滤液 | 0.7 |
o-伞花烃-5-醇 | 0.25 |
黄檗树皮提取物 | 0.125 |
白柳树皮提取物 | 0.05 |
中国地黄根提取物 | 0.04 |
印度楝树叶提取物 | 0.02 |
黄芩根提取物 | 0.018 |
鱼腥草提取物 | 0.016 |
野大豆提取物 | 0.008 |
下面结合实施例,进一步阐述本发明:
实施例1
甘油 | 1% |
丙二醇 | 1% |
丁二醇 | 2% |
寡聚透明质酸 | 0.001% |
β-葡聚糖 | 0.01% |
甜菜碱 | 0.1% |
尿囊素 | 0.05% |
烟酰胺 | 1% |
辛酰基甘氨酸 | 0.1% |
精氨酸 | 0.1% |
痤疮克星 | 0.1% |
硅烷二醇水杨酸酯 | 0.01% |
吡咯烷酮羧酸锌 | 0.01% |
L-抗坏血酸磷酸酯镁 | 0.01% |
积雪草提取物 | 0.01% |
薄荷氧基丙二醇 | 0.01% |
添加黄原胶0.2%,PHL为1%,剩余添加去离子水至100%配制祛痘水组分进行功效评价,其配方工艺如下:
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌、辛酰基甘氨酸和精氨酸加热至75℃,以180r/min,搅拌30min,以6000r/min均质3min;
3)分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至68℃加入,以200r/min,搅拌30min,以8500r/min均质3min;
4)降低搅拌速率至150r/min,温度降至55℃,分别称取积雪草提取物和痤疮克星搅拌20min;
5)温度降低48℃,称量防腐剂PHL和薄荷氧基丙二醇,搅拌10min冷却室温即可。
实施例2
甘油 | 2% |
丙二醇 | 3% |
丁二醇 | 3% |
寡聚透明质酸 | 0.01% |
β-葡聚糖 | 0.1% |
甜菜碱 | 0.5% |
尿囊素 | 0.15% |
烟酰胺 | 2% |
辛酰基甘氨酸 | 0.5% |
精氨酸 | 0.5% |
痤疮克星 | 0.5% |
硅烷二醇水杨酸酯 | 0.5% |
吡咯烷酮羧酸锌 | 0.05% |
L-抗坏血酸磷酸酯镁 | 2% |
积雪草提取物 | 0.3% |
薄荷氧基丙二醇 | 0.03% |
添加黄原胶0.2%,PHL为1%,剩余添加去离子水至100%配制祛痘水组分进行功效评价,其配方工艺如下:
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌、辛酰基甘氨酸和精氨酸加热至80℃,以200r/min,搅拌30min,以7000r/min均质3min;
3)分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至75℃加入,以250r/min,搅拌30min,以9000r/min均质3min;
4)降低搅拌速率至200r/min,温度降至50℃,分别称取积雪草提取物和痤疮克星搅拌25min;
5)温度降低50℃,称量防腐剂PHL和薄荷氧基丙二醇,搅拌10min冷却室温即可。
实施例3
甘油 | 5% |
丙二醇 | 4% |
丁二醇 | 5% |
寡聚透明质酸 | 0.1% |
β-葡聚糖 | 0.5% |
甜菜碱 | 0.8% |
尿囊素 | 0.2% |
烟酰胺 | 5% |
辛酰基甘氨酸 | 1% |
精氨酸 | 1% |
痤疮克星 | 3% |
硅烷二醇水杨酸酯 | 1% |
吡咯烷酮羧酸锌 | 0.1% |
L-抗坏血酸磷酸酯镁 | 3% |
积雪草提取物 | 0.5% |
薄荷氧基丙二醇 | 0.1% |
添加黄原胶0.2%,PHL为1%,剩余添加去离子水至100%配制祛痘水组分进行功效评价,其配方工艺如下:
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌,辛酰基甘氨酸和精氨酸加热至78℃,以150r/min,搅拌30min,以6500r/min均质3min;
3)分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至60℃加入,以220r/min,搅拌30min,以8000r/min均质3min;
4)降低搅拌速率至180r/min,温度降至45℃,分别称取积雪草提取物和痤疮克星搅拌30min;
5)温度降低45℃,称量防腐剂PHL和薄荷氧基丙二醇,搅拌10min冷却室温即可。
对比例1
甘油 | 2% |
丙二醇 | 3% |
丁二醇 | 3% |
寡聚透明质酸 | 0.01% |
β-葡聚糖 | 0.1% |
甜菜碱 | 0.5% |
尿囊素 | 0.15% |
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
3)温度降低45~50摄氏度,称量防腐剂PHL搅拌10min冷却室温即可。
对比例2
甘油 | 2% |
丙二醇 | 3% |
丁二醇 | 3% |
寡聚透明质酸 | 0.01% |
β-葡聚糖 | 0.1% |
甜菜碱 | 0.5% |
尿囊素 | 0.15% |
烟酰胺 | 2% |
辛酰基甘氨酸 | 0.5% |
精氨酸 | 0.5% |
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺,辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
3)称取黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
4)温度降低45~50℃,称量PHL,搅拌10min冷却室温即可。
对比例3
甘油 | 2% |
丙二醇 | 3% |
丁二醇 | 3% |
寡聚透明质酸 | 0.01% |
β-葡聚糖 | 0.1% |
甜菜碱 | 0.5% |
尿囊素 | 0.15% |
烟酰胺 | 2% |
辛酰基甘氨酸 | 0.5% |
精氨酸 | 0.5% |
硅烷二醇水杨酸酯 | 0.5% |
吡咯烷酮羧酸锌 | 0.05% |
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌,辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
3)称取黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
4)温度降低45~50℃,称量PHL,搅拌10min冷却室温即可。
对比例4
甘油 | 2% |
丙二醇 | 3% |
丁二醇 | 3% |
寡聚透明质酸 | 0.01% |
β-葡聚糖 | 0.1% |
甜菜碱 | 0.5% |
尿囊素 | 0.15% |
烟酰胺 | 2% |
辛酰基甘氨酸 | 0.5% |
精氨酸 | 0.5% |
痤疮克星 | 0.5% |
硅烷二醇水杨酸酯 | 0.5% |
吡咯烷酮羧酸锌 | 0.05% |
L-抗坏血酸磷酸酯镁 | 2% |
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌,辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
3)分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
4)降低搅拌速率至150~200r/min,温度降至45~55℃,称取痤疮克星,搅拌20~30min;
5)温度降低45~50℃,称量防腐剂PHL,搅拌10min冷却室温即可。
对比例5
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌,辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
3)分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
4)降低搅拌速率至150~200r/min,温度降至45~55℃,分别称取积雪草提取物和痤疮克星,搅拌20~30min;
5)温度降低45~50℃,称量PHL,搅拌10min冷却室温即可。
对比例6
1)按照工艺配比称量其去离子水;
2)分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸,烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌,辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
3)分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
4)降低搅拌速率至150~200r/min,温度降至45~55℃,分别称取积雪草提取物和痤疮克星,搅拌20~30min;
5)温度降低45~50℃,称量防腐剂PHL和薄荷氧基丙二醇,搅拌10min冷却室温即可。
实施例4经皮水分散失评价
测试原理:
该试验仪器的测量原理来源于FICK菲克扩散定律:
dm/dt=D.A.dp/dx。通过两组温度、湿度传感器测定近表皮(约1cm内)由角质层水分散失在不同亮点形成的水蒸气压梯度,直接测出经皮散发的水分量。TEWL值是皮肤屏障好坏的一个重要标志,皮肤的TEWL值越低,说明皮肤的屏障功能越好,反之越差。
(2)试验条件和志愿者要求
测试环境条件:测试环境温度为22±1℃,湿度为50±5%,并且进行实时动态检测;
志愿者要求:有效志愿者至少30人,年龄在16-65岁之间(妊娠或浦乳期妇女除外):前臂测试区域电容法皮肤水分测定意义的基础值在15-100之间:无严重系统疾病,无免疫缺陷或自身免疫性疾病者;无活动性过敏疾病者;既往对护肤类化妆品无严重过敏史者;近一个月内未曾使用激素类药物及免疫抑制剂者:为参加其他临床试验者;按规定使用受试药物且资料齐全;测试前所有自愿者应填写知情同意书;
(3)测试前准备
受试部位前2-3天不能使用任何产品(化妆品或外用药品)。实验前,受试者需要同意清洁双手前臂内测,用干的面巾纸擦拭干净。清洁后受试者双手前臂内测做好测量区域标记。正式测试前应在符合标准房间内静坐至少30min,不能喝水,前臂暴露,呈测试状态放置,保持放松。
(4)测试步骤
实验中左右手臂内侧标记3*3cm2试验区域,同一手臂可以标记多个区域,区域间隔1cm。测试产品和空白对照均随机分布在左右手臂上。使用电容法皮肤测定仪进行受试区域和对照区域的测量。每个区域依照平行测定15次。先测量各测试区域的空白纸,然后按2.0±0.1mg样品/cm2的用量,使用乳胶指套将试验均匀涂布于试验区内。涂抹分别测量1,2小时,4小时,受试区域和空白对照区域的皮肤含水量(验证时按此时间测定),同一个志愿者的测试由同一个测量人员完成。
测试结果:
按实验设计分别测得各时段的TEWL值。
T%=(T0-T1)/T0*100%
T%:皮肤水分散失减少百分率;
T0:使用样品前初始皮肤水分散失值;
T1:使用样品后皮肤水分散失值;
注:水分散失值减少越大,意味着TWEL越小,皮肤屏障越完好,其具体数值如表1、图1所示。
表1
结论:本发明提供的化妆品水分散失降低达到13.93%-21.92%,可佐证本发明具有很好的修复皮肤屏障功能。
实施例5细胞增殖评测
实验原理:
1)细胞计数方法
细胞计数方法采用的是血细胞计数板,按白细胞计数方法进行计算.细胞悬液制备后,常用活体染料台盼蓝对细胞进行染色,进行细胞计数。台盼蓝不能透过活细胞正常完整的细胞膜,故活细胞不着色。而死亡细胞的细胞膜通透性增高,可使染料进入细胞内而使细胞着色(蓝色)。
实验材料和方法:
实验材料:DMEM、DPBS、Typsin-EDTA、Petridish、96welldish、0.4%台盼蓝溶液、无水乙醇或95%乙醇溶液、普通显微镜、细胞计数板、移液枪、MTT、DMSO
实验方法:
成纤维细胞培养:
1)将培养好的成纤维细胞用Typsin-EDTA处理后收集,用DMEM悬浮后利用血细胞计数板计数后将悬浮液稀释到细胞的浓度为5×104cells/ml备用
2)将准备好的细胞悬浮液分别分株到96well dish和6well dish中培养,其中96well dish接种量为100ul,6well dish接种量为2ml。
3)在37℃,5%CO2的培养箱中培养24小时。
样品添加:
1)待测样品用DMEM培基稀释,稀释后的浓度分别为:1%(该浓度通过前面的MTT测试,结果为无毒)
2)细胞培养24小时后,移除之前的DMEM,然后用DPBS小心洗涤后
3)按照顺序加入第一步准备的添加了待测样品的DMEM培养基。
4)在37℃,5%CO2的培养箱中培养48小时。
细胞计数:
1)计数板处理
用无水乙醇或95%乙醇溶液擦拭计数板后,用绸布擦净,另擦净盖玻片一张,把盖片覆在计数板上面。
2)染色
取6well dish培养的细胞,除去培养基后,利用typsin-EDTA消化,收集细胞后用DMEM培养基悬浮。用移液枪吸取10ul 0.4%台盼蓝染液和10ul细胞悬液混合均匀。从计数板边缘缓缓注入,使之充满计数板和盖片之间的空隙中。将计数板放在低倍镜下(10×10倍)观察计数。
3)计数方法
按图计算计数板的四角大方格(每个大方格又分16个小方格)内的细胞数。计数时,只计数完整的细胞,若聚成一团的细胞则按一个细胞进行计数。在一个大方格中,如果有细胞位于线上,一般计下线细胞不计上线细胞,计左线细胞不计右线细胞。镜下观察,凡折光性强而不着色者为活细胞,染上蓝色者为死细胞。
4)计数的换算
计完数后,换算出每ml悬液中的细胞数。由于计数板中每一方格的面积为0.01cm2,高为0.01cm,这样它的体积为0.0001cm3,即0.1mm3。由于1ml=1000mm3,所以每一大方格内细胞数×10 000=细胞数/ml,故可按下式计算:
细胞悬液细胞数/ml=4个大格细胞总数/4×10000
如计数前已稀释,可再乘稀释倍数。计数细胞后,计算可得到细胞悬液中细胞的浓度。以空白样为基准,计算出各个样品的细胞增殖率。
成纤维细胞增值结果:
见图2。
结论:本发明提供的化妆品能够提升成纤维细胞增殖达42.42%~58.43%,与对比例相比具有显著差异(P<0.05),表明本发明提供的化妆品针对痤疮皮损具有较强的愈合恢复能力。
实施例6细胞产生的黑色素量测试
5.3.1实验材料:B16F10,DMEM培养基,胰蛋白酶,DPBS,70%酒精,NaOH,DMSO
5.3.2实验方法:
(1)将B16F10细胞消化后,利用DMEM培基分散细胞,利用Hemacytometer来计数细胞,然后利用DMEM来稀释细胞,稀释到浓度为5×104cells/ml。
(2)稀释后的细胞溶液分别接种到6well中,每一孔为2ml,即1×105cells/well。
(3)在37℃,5%CO2的培养箱中培养24小时。
(4)待测样品准备:待测样品用DMEM培基稀释,稀释后的浓度分别为:50%(该浓度通过前面的MTT测试,结果为无毒)
(5)细胞培养24小时后,观察细胞是否完全贴壁生长,如果细胞完全贴壁生长的话,将原培基移除,用DPBS洗涤。
(6)将DPBS移除之后,分别加入前面准备好的样品。样品的溶度根据毒性测试的结果选择安全浓度100ppm(2ml/well)。
(7)样品加入之后,放入37℃,5%CO2的培养箱中培养48小时。
(8)分别收集培基和细胞,分别测试细胞外与细胞内的黑色素的含量
(9)培基部分:13500rpm x 10mins离心后,取上层清液在波长415nm处测量吸光光度。
(10)细胞部分:将B16F10细胞消化后收集起来,13500rpm x 10mins离心后,移除上层清液。底部的B16F10细胞中加入0.3ml的10%DMSO,1N NAOH溶液,80℃水浴中裂解1小时。
(11)1小时后裂解液冷却至室温,13500rpm x 10mins离心后收集上层清液
(12)利用酶标仪在波长415nm处测量上层清液的吸光光度OD。
(13)配置黑色素标样,浓度为1.0到100.0ppm,分别测试标样的吸光光度,绘制出浓度与吸光光度的线性关系图
(14)利用上述的线性关系图可以得出细胞内与细胞外黑色素的含量。
5.3.3实验结果如图3、表2所示。
其具体数值表如下:
表2
结论:本发明提供的化妆品在细胞内,细胞外均具有降低细胞内黑色素含量的功效,空白样黑色素含量高达257.38ppm,而实例样黑色素含量仅109.94ppm,降低了147.44ppm,表明本发明提供的化妆品能显著(P<0.05)抑制因痤疮炎症引起的细胞黑色素沉着。
实施例7祛痘临床表征评价
纳入标准:
1)符合Pillshury I\II级痤疮诊断标准:I级,颜面部,粉刺为主,少量丘疹,脓疱,总皮损<30个;II级,颜面部,粉刺和中等丘疹、脓疱,总皮损数(30-50)个;
2)无明确系统性疾病;
3)受试者在整个测试期间,不食辛辣,甜食并忌酒等;
4)测试前2周未使用过其它祛痘产品或接受其它治疗方法(如果酸,激光治疗等);
5)整个观察测试期间不使用其它祛痘产品及接受其它治疗方法(包括光疗)
排除标准:
1)妊娠,拟妊娠,浦乳期妇女;
2)直接参与此项研究的工作人员;
3)面部有其它皮肤疾病,例如黄褐斑,脂溢性皮炎,酒糟鼻;
样品试用:
分别甄选符合I级、II级标准人员、以及对各5名,早晚使用测试样品,每周一进行VISA进行面部拍照评价,持续四周,根据治愈率进行祛痘功效评价。
以其中一名参与评估人员皮肤3D图如图4所示。
结论:本发明提供的化妆品给到痤疮患者,经过为期四周的评测,从皮肤3D图能够明显表征本发明具有较好的促进痤疮皮损愈合的功效。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.一种组合物,其特征在于,以质量份计,包括:
其中,以质量分数计,所述痤疮克星的组成为:
2.根据权利要求1所述的组合物在制备治疗和/或预防皮肤屏障受损、青春痘发红发热炎、局部色素沉着、青春痘导致胶原蛋白降解与合成失衡形成的皮肤凹陷和疤痕的药物和/或化妆品中的应用。
3.根据权利要求1所述的组合物在制备治疗和/或预防痤疮的药物和/或化妆品中的应用。
4.一种化妆品,其特征在于,包括如权利要求1所述的组合物以及化妆品中可接受的辅料。
5.根据权利要求4所述的化妆品,其特征在于,以质量分数计,包括:
其中,所述痤疮克星的组成为:
6.根据权利要求4或5所述的化妆品的制备方法,其特征在于,包括如下步骤:
步骤1:称量去离子水;
步骤2:分别称量甘油、丙二醇、丁二醇、甜菜碱、尿囊素、β-葡聚糖、寡聚透明质酸、烟酰胺、硅烷二醇水杨酸酯、吡咯烷酮羧酸锌、辛酰基甘氨酸和精氨酸,加热至75~80℃,以150~200r/min,搅拌30min,以6000~7000r/min均质3min;
步骤3:分别称取L-抗坏血酸磷酸酯镁,黄原胶,降温至60~75℃加入,以200~250r/min,搅拌30min,以8000~9000r/min均质3min;
步骤4:降低搅拌速率至150~200r/min,温度降至45~55℃,称取积雪草提取物和痤疮克星,搅拌20~30min;
步骤5:温度降低45~50℃,称量防腐剂PHL和薄荷氧基丙二醇,搅拌10min冷却。
7.根据权利要求4或5所述的化妆品或如权利要求6所述的制备方法制得的化妆品在制备治疗和/或预防皮肤屏障受损、青春痘发红发热炎、局部色素沉着、青春痘导致胶原蛋白降解与合成失衡形成的皮肤凹陷和疤痕的药物和/或化妆品中的应用。
8.根据权利要求4或5所述的化妆品或如权利要求6所述的制备方法制得的化妆品在制备治疗和/或预防痤疮的药物和/或化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810264475.XA CN108272740B (zh) | 2018-03-28 | 2018-03-28 | 组合物及含有该组合物的痤疮修复化妆品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810264475.XA CN108272740B (zh) | 2018-03-28 | 2018-03-28 | 组合物及含有该组合物的痤疮修复化妆品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108272740A CN108272740A (zh) | 2018-07-13 |
CN108272740B true CN108272740B (zh) | 2019-03-12 |
Family
ID=62810770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810264475.XA Active CN108272740B (zh) | 2018-03-28 | 2018-03-28 | 组合物及含有该组合物的痤疮修复化妆品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108272740B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619062B (zh) * | 2018-07-17 | 2020-06-19 | 广州澳希亚实业有限公司 | 祛痘组合物及其应用 |
EP3964211A1 (en) * | 2020-09-07 | 2022-03-09 | DSM IP Assets B.V. | A composition comprising an ascorbyl phosphate, niacinamide and allantoin for treating acne |
CN112107514A (zh) * | 2020-09-22 | 2020-12-22 | 鲁南制药集团股份有限公司 | 一种抗皱护肤品组合物及其用途 |
CN113662904B (zh) * | 2021-08-11 | 2023-09-22 | 中山市天图精细化工有限公司 | 一种祛痘贴片气雾剂及其制备方法 |
CN114569536B (zh) * | 2022-03-01 | 2023-07-28 | 山东福瑞达生物股份有限公司 | 一种对衰老皮肤微生态和皮肤生理状态有改善作用的乳液 |
CN115844796A (zh) * | 2022-12-27 | 2023-03-28 | 陕西慧康生物科技有限责任公司 | 具有祛痘、焕肤、缓释功效的油包水组合物及应用 |
CN116098845A (zh) * | 2023-03-06 | 2023-05-12 | 深圳市前海中天云舒管理有限公司 | 一种祛痘修护面膜及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1284971B1 (it) * | 1996-10-17 | 1998-05-28 | Indena Spa | Formulazioni farmaceutiche e cosmetiche ad attivita' antiacne |
CN103767959A (zh) * | 2012-10-28 | 2014-05-07 | 烟台大洋制药有限公司 | 一种含有积雪草的洁面乳 |
CN105125431A (zh) * | 2015-07-28 | 2015-12-09 | 上海贝泰妮生物科技有限公司 | 具有祛痘功效的祛痘功效组合物、面膜及其制备方法 |
CN107349149A (zh) * | 2017-07-25 | 2017-11-17 | 广州铭心化妆品有限公司 | 一种祛痘精华液及其制备方法 |
-
2018
- 2018-03-28 CN CN201810264475.XA patent/CN108272740B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN108272740A (zh) | 2018-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108272740B (zh) | 组合物及含有该组合物的痤疮修复化妆品 | |
CN108478518A (zh) | 一种组合物及含有该组合物的祛痘化妆品 | |
CN107714531B (zh) | 抗敏舒缓组合物及其应用 | |
CN106727147B (zh) | 草本洋参皮肤美容改善药物及化妆品应用和制备 | |
CN105381007B (zh) | 具有美白功效的外用中药组合物、制剂及其制备方法和用途 | |
CN101849899A (zh) | 一种中药复方提取物及含有所述活性成分的化妆品 | |
CN108158972A (zh) | 组合物及含有该组合物的抑制痤疮炎症的化妆品 | |
CN110384653A (zh) | 一种具有多方位祛黄功效的多肽精华液及其制备工艺 | |
KR101374327B1 (ko) | 장수말벌독 추출물을 이용한 기능성 화장료 조성물 | |
CN115154383B (zh) | 一种温和美白组合物及其美白面霜 | |
CN109431914A (zh) | 头皮养护组合物及其应用 | |
CN108392434A (zh) | 一种蚕丝提取物、及含其的美白祛斑组合物和制备方法 | |
CN105662905A (zh) | 二氢杨梅素在制备防治皮肤光损伤护肤品或药品中的用途 | |
CN107157787A (zh) | 抑制黑色素沉着组合物及其应用 | |
Kaminaka et al. | Effects of low‐dose Aloe sterol supplementation on skin moisture, collagen score and objective or subjective symptoms: 12‐week, double‐blind, randomized controlled trial | |
CN107260612B (zh) | 祛除黄褐斑组合物、应用、复合制剂及制备方法 | |
CN113440446A (zh) | 祛斑组合物及其应用和祛斑护理膜片 | |
CN117815216A (zh) | 抗光老化和/或真皮色素沉着抑制剂 | |
CN116473856A (zh) | 一种美白亮肤面膜精华液及其制备方法、一种美白亮肤面膜 | |
CN105125651A (zh) | 一种美白淡斑组合物及其制备方法、使用方法 | |
CN104784475B (zh) | 一种用于美白祛斑的中药组方提取物及其应用 | |
KR100406124B1 (ko) | 자외선에 의해 증가하는 프로스타글란딘을 억제하는성분과 멜라닌 합성을 억제하는 성분을 동시에 함유하는미백 화장료 조성물 | |
KR20010038100A (ko) | 생약재 추출물을 함유하는 미백 화장료 조성물 | |
CN116270349B (zh) | 组合物及其制备方法和应用 | |
Yuan et al. | Topical, light‐based, and complementary interventions for acne: an overview of systematic reviews |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 410000 No. 390, Guyuan Road, Changsha hi tech Development Zone, Changsha City, Hunan Province Patentee after: Shuiyang Cosmetics Manufacturing Co.,Ltd. Address before: No.668, Qingshan Road, Changsha high tech Development Zone, Changsha, Hunan Province Patentee before: HUNAN YUJIA COSMETICS MANUFACTURING Co.,Ltd. |